Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis

Kayla J. Krause; David Goldrich; John Gniady

doi:10.1002/lary.30527

Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis

Kayla J. Krause, David Goldrich, John Gniady

Research output: Contribution to journal › Article › peer-review

Abstract

Recurrent respiratory (RRP) or laryngeal papillomatosis is the result of human papillomavirus-mediated benign tumor growth on the larynx and is challenging to manage. Benralizumab is a monoclonal antibody targeted against the alpha subunit of the IL-5 receptor on eosinophils. A 61-year-old male patient presented with refractory RRP following multiple surgical excisions. His disease course improved substantially when benralizumab was added to his asthma regimen. There is no clear mechanistic role suggested for benralizumab directly treating RRP. This case may represent a novel application of benralizumab as an adjuvant treatment for patients with RRP and comorbid asthma. Laryngoscope, 133:863–865, 2023.

Original language	English (US)
Pages (from-to)	863-865
Number of pages	3
Journal	Laryngoscope
Volume	133
Issue number	4
DOIs	https://doi.org/10.1002/lary.30527
State	Published - Apr 2023

All Science Journal Classification (ASJC) codes

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/lary.30527

Cite this

@article{6d42a41568ee4793830e4882fa9c8fca,

title = "Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis",

abstract = "Recurrent respiratory (RRP) or laryngeal papillomatosis is the result of human papillomavirus-mediated benign tumor growth on the larynx and is challenging to manage. Benralizumab is a monoclonal antibody targeted against the alpha subunit of the IL-5 receptor on eosinophils. A 61-year-old male patient presented with refractory RRP following multiple surgical excisions. His disease course improved substantially when benralizumab was added to his asthma regimen. There is no clear mechanistic role suggested for benralizumab directly treating RRP. This case may represent a novel application of benralizumab as an adjuvant treatment for patients with RRP and comorbid asthma. Laryngoscope, 133:863–865, 2023.",

author = "Krause, {Kayla J.} and David Goldrich and John Gniady",

note = "Publisher Copyright: {\textcopyright} 2022 The American Laryngological, Rhinological and Otological Society, Inc.",

year = "2023",

month = apr,

doi = "10.1002/lary.30527",

language = "English (US)",

volume = "133",

pages = "863--865",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis

AU - Krause, Kayla J.

AU - Goldrich, David

AU - Gniady, John

PY - 2023/4

Y1 - 2023/4

N2 - Recurrent respiratory (RRP) or laryngeal papillomatosis is the result of human papillomavirus-mediated benign tumor growth on the larynx and is challenging to manage. Benralizumab is a monoclonal antibody targeted against the alpha subunit of the IL-5 receptor on eosinophils. A 61-year-old male patient presented with refractory RRP following multiple surgical excisions. His disease course improved substantially when benralizumab was added to his asthma regimen. There is no clear mechanistic role suggested for benralizumab directly treating RRP. This case may represent a novel application of benralizumab as an adjuvant treatment for patients with RRP and comorbid asthma. Laryngoscope, 133:863–865, 2023.

AB - Recurrent respiratory (RRP) or laryngeal papillomatosis is the result of human papillomavirus-mediated benign tumor growth on the larynx and is challenging to manage. Benralizumab is a monoclonal antibody targeted against the alpha subunit of the IL-5 receptor on eosinophils. A 61-year-old male patient presented with refractory RRP following multiple surgical excisions. His disease course improved substantially when benralizumab was added to his asthma regimen. There is no clear mechanistic role suggested for benralizumab directly treating RRP. This case may represent a novel application of benralizumab as an adjuvant treatment for patients with RRP and comorbid asthma. Laryngoscope, 133:863–865, 2023.

UR - http://www.scopus.com/inward/record.url?scp=85144176972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144176972&partnerID=8YFLogxK

U2 - 10.1002/lary.30527

DO - 10.1002/lary.30527

M3 - Article

C2 - 36524437

AN - SCOPUS:85144176972

SN - 0023-852X

VL - 133

SP - 863

EP - 865

JO - Laryngoscope

JF - Laryngoscope

IS - 4

ER -

Benralizumab as an Adjuvant Therapy for Recurrent Laryngeal Papillomatosis

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this